All relevant data are within the paper and its Supporting Information files.

Introduction {#sec001}
============

More than 3,000 human genes encode transmembrane proteins that have been classified into receptors, transporters, enzymes, and other proteins \[[@pone.0235563.ref001]\]. Transmembrane proteins such as solute carrier (SLC) transporters play vital roles in import and export of nutrients, metabolites, and ions. Examples of SLC substrates are sugars, amino acids, vitamins, neurotransmitters, urea cycle metabolites, and metals \[[@pone.0235563.ref002], [@pone.0235563.ref003]\] including iron \[[@pone.0235563.ref004]\]. The human SLC transporter families comprise more than 400 genes and 52 subfamilies under the SLC family clusters, including MFS (major facilitator superfamily) and APC (amino acid-polyamine-organocation) superfamily \[[@pone.0235563.ref003], [@pone.0235563.ref005], [@pone.0235563.ref006]\]. The majority of SLC transporter proteins has 12-transmembrane segment (TMS) with diversities typically ranging from 9 to 14 TMS \[[@pone.0235563.ref007]\].

Iron metabolism is coordinately regulated by iron import, export, and storage proteins localized in plasma membrane and intracellular compartments \[[@pone.0235563.ref008]--[@pone.0235563.ref010]\]. For instance, human transferrin receptor-1 (TfR1) is an 85 KDa homodimer of a plasma single-transmembrane protein serving as a major iron importing receptor for transferrin bound to two molecules of ferric iron (Fe^3+^) \[[@pone.0235563.ref011], [@pone.0235563.ref012]\]. Iron is also subject to import and export by SLC transmembrane transporters. One is SLC11A1 and A2; particularly SLC11A2 (Divalent Metal Transporter---DMT1 or NRAMP2) which is a ubiquitously expressed transporter of iron along with cadmium, cobalt, manganese, and zinc to a lesser extent \[[@pone.0235563.ref013]--[@pone.0235563.ref015]\]. DMT1 plays a pivotal role in apical iron (Fe^2+^) absorption (after Fe^3+^ is reduced by ferric reductase DcytB, \[[@pone.0235563.ref016]\]) into duodenal enterocytes \[[@pone.0235563.ref013], [@pone.0235563.ref017], [@pone.0235563.ref018]\]. DMT1 also transports endosomal iron released from transferrin (and reduced by Steap3) into the cytoplasm for supply of ferrous iron (Fe^2+^) in various cell types \[[@pone.0235563.ref008]\]. The DMT1 gene encodes four isoforms of mRNAs through alternative promoter and splicing \[[@pone.0235563.ref017], [@pone.0235563.ref019], [@pone.0235563.ref020]\], giving rise to at least four different DMT1 proteins \[[@pone.0235563.ref019]\]. The four isoforms of human DMT1 are 61--65 KDa transmembrane proteins having 12-TMS \[[@pone.0235563.ref013], [@pone.0235563.ref015], [@pone.0235563.ref021]\]. Another SLC protein in charge of iron export is SLC40A1 (Ferroportin 1---Fpn1 or IREG1) that is highly expressed in basolateral membrane of duodenal enterocytes and exports iron into blood stream \[[@pone.0235563.ref022]--[@pone.0235563.ref024]\], where Fe^2+^ is oxidized to Fe^3+^ by membrane-bound hephaestin or ceruloplasmin circulating in blood stream, transferring Fe^3+^ to transferrin for systemic delivery of iron (Fe^3+^) \[[@pone.0235563.ref025]\]. Fpn1 is also highly expressed in reticuloendothelial macrophages that release iron for recycling after erythrophagocytosis \[[@pone.0235563.ref026], [@pone.0235563.ref027]\]. Fpn1 is a 63 kDa multipass transmembrane protein predicted to contain 12-TMS \[[@pone.0235563.ref028], [@pone.0235563.ref029]\]. Hepcidin, a 25-amino acid peptide secreted from the liver in response to iron overload and inflammation \[[@pone.0235563.ref030]--[@pone.0235563.ref032]\], binds and induces internalization and degradation of Fpn1 leading to decrease in plasma iron levels and iron distribution to tissues \[[@pone.0235563.ref033]\]. When Fe^2+^ levels are more than what cells need, the surplus of iron is stored into ferritin shell composed of 24 multi-subunits of tissue-specific ratios of H (heavy) and L (light) chains \[[@pone.0235563.ref011], [@pone.0235563.ref034], [@pone.0235563.ref035]\]. Iron (Fe^2+^) is stored in ferritin shell as Fe^3+^ catalyzed by the ferroxidase activity of the ferritin H subunit \[[@pone.0235563.ref034]\].

Western blotting is an important technique to investigate protein expression, posttranslational modifications (e.g. phosphorylation), and interactions with other proteins and macromolecules, in which we mostly use commercially available antibodies for detection of proteins of our interests. There are numerous monoclonal and polyclonal antibodies successfully used for western blotting and other applications (CiteAb, <https://www.citeab.com/>), while we still experience antibodies not working or far below our expectation of qualities for unknown reasons. To verify the quality and specificity of antibodies, we should take positive and negative control samples such as cell lysates prepared after transient transfection of expression plasmids or knockdown of endogenous mRNAs. In particular, detection of transmembrane proteins in western blotting has often been challenging due to difficulties in solubilization of those proteins with detergents and reducing agents. There are numerous numbers of transmembrane protein western blots so far published, including DMT1 and Fpn1 proteins (CiteAb). In this report, we initially judged our DMT1 and Fpn1 antibodies not working in our routine western blotting protocol; however, reassessment and modification of our protocol in a sample preparation step significantly improved the resolution of western blots.

Materials and methods {#sec002}
=====================

Cell culture and maintenance {#sec003}
----------------------------

12 human cell lines used in this study and their culture media are listed in [Table 1](#pone.0235563.t001){ref-type="table"}. All cell lines were cultured at 37°C in a humidified CO~2~ incubator (5% CO~2~, Sanyo model MCO-17AIC). Undifferentiated Caco-2 cells were used in this study. Adherent cells were passaged by trypsinization (0.25% Trypsin, 2.6 mM EDTA in calcium/magnesium free PBS) every 3--5 days when they were confluent. Suspension cells were passaged by 20\~30-fold dilution to fresh growth media every 4--6 days.

10.1371/journal.pone.0235563.t001

###### All chemicals and reagents used in this study.

![](pone.0235563.t001){#pone.0235563.t001g}

  REAGENT OR RESOURCE                                SOURCE                                                                IDENTIFIER (catalog \#)
  -------------------------------------------------- --------------------------------------------------------------------- ----------------------------------------------------
  ***Antibodies***                                                                                                         
  Mouse monoclonal anti-ferritin H                   Santa Cruz Biotechnology                                              sc-135667 (3F8)
  Rabbit polyclonal anti-transferrin receptor        Abcam                                                                 ab84036
  Rabbit monoclonal anti-DMT1/SLC11A2                Cell Signaling Technology                                             15083 (D3V8G)
  Rabbit polyclonal anti-ferroportin 1(SLC40A1)      Novus Biologicals                                                     NBP1-21502
  Mouse monoclonal anti-GAPDH                        Chemicon                                                              MAB374
  Mouse monoclonal anti-Flag                         Sigma-Aldrich                                                         F3165
  Goat anti-mouse IgG-peroxidase conjugated          Millipore                                                             AP181P
  Goat anti-rabbit IgG-peroxidase conjugated         Millipore                                                             AP132P
  ***Chemicals/Culture Media***                                                                                            
  Dulbecco\'s modified Eagle Medium (DMEM)           Corning                                                               50-003-PC
  Minimum Essential Medium (MEM)                     Corning                                                               50-011-PC
  RPMI1640                                           Corning                                                               50-020-PC
  Ham\'s F12                                         Corning                                                               50-040-PB
  Opti-MEM                                           Life Technologies                                                     22600--134
  Penicillin Streptomycin solution, 100X             Corning                                                               30-002-CI
  Sodium pyruvate                                    Corning                                                               MT25000CI
  Non-essential amino acid solution, 100X            Corning                                                               25-025-CI
  Trypsin, 10X                                       Corning                                                               25-054-CI
  Fetal Bovine Serum                                 Seradigm                                                              1400--500
  Ammonium iron(III) citrate (FAC)                   Sigma-Aldrich                                                         F5879
  Deferoxamine mesylate salt (DFO)                   Sigma-Aldrich                                                         D9533
  Hemin                                              Fluka                                                                 51280
  Acrylamide                                         J.T. Baker                                                            4081--01
  Bis-Acrylamide                                     EMD Millipore                                                         2620
  Sodium dodecyl sulfate (SDS)                       Calbiochem                                                            7910
  Sodium deoxycholate                                Sigma-Aldrich                                                         D-6750
  Nonidet-P40 (NP40)                                 US Biological                                                         N-3500
  Tris (Hydroxymethyl) Aminomethane                  J.T. Baker                                                            4109--06
  Glycine                                            J.T. Baker                                                            4057--06
  Sodium chloride                                    BDH                                                                   7647-14-5
  Ammonium persulfate                                Thermo Scientific                                                     17874
  TEMED                                              Fisher                                                                BP150-100
  Skim milk powder                                   EMD Millipore                                                         1.15363.0500
  Bovine Serum Albumin (BSA) Fraction V              EMD Millipore (Calbiochem)                                            2930
  Tween 20                                           Fisher                                                                BP337-500
  2-mercaptoethanol                                  EMD Millipore                                                         6050
  Glycerol                                           Fisher                                                                BP229-1
  Bromophenol blue                                   Sigma-Aldrich                                                         B-8026
  Hepcidin                                           Peptide Institute, Inc.                                               PLP-4392-s
  HyGLO Chemiluminescent HRP Detection Reagent       Denville Scientific                                                   E2500
  Pierce ECL Western Blotting substrate              Thermo Scientific                                                     32106
  Clarity Western ECL Substrate                      Bio-Rad                                                               170--5061
  Protein Assay Dye Reagent Concentrate              Bio-Rad                                                               5000006
  Precision Plus Protein Dual Color Standards        Bio-Rad                                                               161--0374
  Protease Inhibitor Cocktail Set I                  Calbiochem/Millipore                                                  539131
  Transmembrane Protein Extraction Reagent           FIVEphoton Biochemicals                                               TmPER-50
  Nco I                                              New England Biolabs                                                   R0193S
  Hind III                                           New England Biolabs                                                   R0104S
  SmaI                                               New England Biolabs                                                   R0141S
  DNA polymerase Klnenow fragment                    New England Biolabs                                                   M0210L
  Lipofectamine RNAiMax                              Invitrogen                                                            13778--150
  ***Cell lines***                                   ***Source/Culture Media****(containing 1x Penicillin Streptomycin)*   
  HaCaT immortalized human keratinocyte              NE Fusenig/ DMEM high glucose (4.5g/L) +10%FBS                        Boukamp et. al J. Cell Biol., 106: 761--771 (1988)
  HepG2 human hepatocellular carcinoma               ATCC/ MEM +10% FBS                                                    HB-8065
  HEK293 immortalized human embryonic kidney cells   ATCC/ MEM +10% FBS                                                    CRL-1573
  HeLa human cervix adenocarcinoma                   ATCC/ MEM +10% FBS                                                    CCL-2
  K562 human erythroleukemia                         ATCC/ RPMI1640, 25 mM HEPES +10%FBS                                   CCL-243
  SW480 human colon adenocarcinoma                   ATCC/ DMEM high glucose (4.5g/L) +10%FBS                              CCL-228
  A549 human lung carcinoma                          Sigma-Aldrich/ DMEM high glucose +10%FBS                              86012804
  HL60 human promyelocytic leukemia                  ATCC/ RPMI1640, 25 mM HEPES +10%FBS                                   CCL-240
  MCF7 human breast adenocarcinoma                   ATCC/ MEM +10% FBS                                                    HTB-22
  SH-SY5Y human neuroblastoma                        ATCC/ MEM:Ham\'s F12(1:1) +10% FBS                                    CRL-2266
  Jurkat human acute T cell leukemia, clone E6-1     ATCC/ RPMI1640, 25 mM HEPES, high glucose +10%FBS                     TIB-152
  Caco-2 human colorectal carcinoma                  ATCC/ MEM +20%FBS                                                     HTB-37
  ***plasmid DNA***                                                                                                        
  pCMVSPORT6 SLC40A1                                 Dharmacon                                                             MHS6278-202801506
  pBluescriptR SLC11A2(DMT1)                         Open Biosystems                                                       MHS1010-98075408
  pRK5SLC11A2(DMT1)                                  this work                                                             
  pCMVFlagSLC40A1(DMT1)                              this work                                                             

Chemicals, and reagents {#sec004}
-----------------------

All chemicals and reagents used in this study, their suppliers, and catalog numbers are listed in [Table 1](#pone.0235563.t001){ref-type="table"}. Ferric ammonium citrate (FAC) and desferrioxamine (DFO) were dissolved in distilled water at 100mM and 25mM, respectively. Hemin was dissolved in 0.1M NaOH at 50mM. Human bioactive hepcidin was dissolved in water at 0.5mM, added to undifferentiated Caco-2 culture at 0.5uM, and incubated for 18--24 hr.

Western blot and antibodies {#sec005}
---------------------------

Whole cell lysates (WCLs) were prepared from sub-confluent or confluent cells grown in 60 mm culture plates (Greiner, 628160). In some experiments, cells were treated with FAC, DFO, or hemin for 18--24 hr before harvest. Cells were washed with phosphate buffered saline (PBS: 137mM NaCl, 27mM KCl, 15mM KH~2~PO~4~, 81mM Na~2~HPO~4~) and lysed in 200-400ul of PBS-based RIPA buffer (1X PBS, 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS) containing 1X protease inhibitor cocktail (Calbiochem/Millipore). In [Fig 2](#pone.0235563.g002){ref-type="fig"}, we also prepared HEK293 WCL in RIPA buffer sonicated for 10 sec. three times in ice-water (550 Sonic Dismembrator, Fisher) or WCL in transmembrane extraction reagent (Five Photon Biochemicals). We did not centrifuge WCLs to remove DNA or debris. Protein concentrations in WCLs were measured with 1X Bio-Rad protein assay dye reagent. 15--30 ug of WCLs were mixed with 2X SDS-PAGE (polyacrylamide gel electrophoresis) sample buffer containing 62.5mM Tris-HCl (pH 6.8), 25% Glycerol, 2% SDS, 0.01% bromophenol blue, and 5% β-mercaptoethanol. The volume of 2X SDS-PAGE sample buffer was equal or more than varied WCL volumes for an equal amount of total proteins. For preparation of heated and non-heated samples, one group was heated at 95°C for 5min in a dry bath incubator (11-718-2, Fisher) containing water in a heating block, while another group was left at room temperature. After briefly spinning down sample tubes, WCLs were loaded on 10% SDS-PAGE (10% acrylamide, 0.27% bisacrylamide, 375mM Tris-HCl pH 8.8, and 0.1% SDS) mini-gel (4x2.9 inches). The stacking gel was 5% acrylamide containing 0.13% bisacrylamide, 125mM Tris-HCl pH 6.8, and 0.1% SDS. Protein size markers (Bio-Rad Precision Plus Protein Standards) was loaded without heating. The electrophoresis was run at 12.5mA per mini-gel for approximately 1.5hr in the running buffer containing 25mM Tris, 192mM Glycine, and 0.1% SDS. Proteins separated on the gel were transferred to PVDF membrane (Thermo Scientific, 88518) in a mini trans-blot cell (Bio-Rad, 022711PM) at 300mA in a transfer buffer (25mM Tris pH 8.3, 192mM Glycine, and 20% methanol) at 4°C for 1.5--2hr. The PVDF membrane was blocked for 20-30min at room temperature in either 1% BSA or 5% skim milk dissolved in 0.1% Tween 20-containing Tris-buffered saline (TBS: 20mM Tris-HCl pH 7.6 and 137mM NaCl) and incubated with a primary antibody on a rocker platform (Speci-Mix, Thermolyne) at 4°C overnight. The primary antibodies for western blots listed in [Table 1](#pone.0235563.t001){ref-type="table"} were diluted with either 5% skim milk in 0.1% Tween/TBS for anti-ferritin H (1:1,000), anti-TfR1 (1:20,000), anti-DMT1/SLC11A2 (1:1,000), anti-GAPDH (1:5,000), anti-Flag (1:1,500), or 1% BSA in 0.1% Tween/TBS for anti-Fpn1/SLC40A1 (1:1,000\~1,500). The PVDF membranes were washed with approximately 50 ml of 0.1% Tween/TBS for 10-20min, three times at room temperature, and incubated with a secondary antibody as listed in [Table 1](#pone.0235563.t001){ref-type="table"} (5,000--8,000-fold diluted with the same dilution solution as a primary antibody, either 5% skim milk or 1% BSA in 0.1% Tween/TBS) for 1.5hr at room temperature. The PVDF membranes were washed with 0.1% Tween/TBS three times, incubated with ECL reagents ([Table 1](#pone.0235563.t001){ref-type="table"}) at room temperature, and exposed to X-ray films (ProSignal Blotting Film, Genesee Scientific 30-507L or 30-810L). For successive incubation with another primary antibody, the membrane was soaked at room temperature for 1 hr in the stripping solution (pH 2.2 with HCl) containing 1.5% glycine, 0.1% SDS, and 1% Tween 20 (from Abcam's western blot membrane stripping for restaining protocol). After washing membrane in 0.1% T/TBS for 15min three times, the procedure was repeated from blocking the membrane with 1% BSA or 5% skim milk in 0.1% T/TBS.

Isolation of cytoplasmic and nuclear fractions {#sec006}
----------------------------------------------

Cells were washed with PBS, resuspended in 200-500ul hypotonic buffer (20mM Tris-HCl, pH 7.4, 10mM NaCl, 3mM MgCl~2~) at 4°C for 15min, then mixed with 1/20 volume of 10% NP40, vortexed for 10 sec, and centrifuged at 12,000 rpm for 30 sec. The supernatant was recovered (cytoplasmic fraction), and the pellet was resuspended in 30-50ul of extraction buffer containing 100mM Tris, pH 7.4, 2mM Na~3~VO~4~, 100mM NaCl, 1% Triton X-100, 1mM EDTA, 10% glycerol, 1mM EGTA, 0.1% SDS, 1mM NaF, 0.5% deoxycholate, 20mM Na~4~P~2~O~7~, and 1X proteinase inhibitor cocktail. The pellet suspension was vortexed for 10 sec, incubated on ice for more than 30min, vortexed for 30 sec, and centrifuged at 12,000 rpm for 10min at 4°C. The supernatant (nuclear fraction) was recovered.

Plasmids, siRNA, and transfection {#sec007}
---------------------------------

pCMVSport6Fpn1 (MGC human SLC40A1 sequence-verified cDNA, clone ID: 5213437, MHS6278-202801506) was purchased from GE Dharmacon. pBluescriptR-DMT1 (SLC11A2 MGC human clone ID: 5300266, MHS1010-98075408) was purchased from Open Biosystems. The 2.5kb DMT1 cDNA was isolated after digestion with NcoI and HindIII followed by filling-in with DNA pol. Klenow fragment, and cloned into SmaI site of pCMV and pCMVFlag vectors. These plasmid DNAs, verified by DNA sequencing (Eurofins), were transiently transfected into HEK293 cells by electroporation (X-Cell, Bio-Rad) as described previously \[[@pone.0235563.ref036]\].

Human Fpn1 siRNA was purchased from Sigma-Aldrich (`GAUGGAACUUGGUAUCCAU`\[dT\]\[dT\], and `AUGGAUACCAAGUUCCAUC`\[dT\]\[dT\]) and 5ul of 20uM solution was transfected into Caco-2 cells (grown in 2ml media/35 mm plate) with 200ul of Opti-MEM containing 6ul of Lipofectamine RNAiMax (Invitrogen) for 18hr, followed by treatment with 250 and 500uM FAC for additional 8hr in the presence of siRNA prior to harvest. Knockdown of Fpn1 in Caco-2 cells was first verified by qPCR as described previously \[[@pone.0235563.ref037]\] using three sets of human Fpn1 primers.

1.  Set1 forward: `5’-CTACTTGGGGAGATCGGATGT-3’`

2.  Set1 reverse: `5’-CTGGGCCACTTTAAGTCTAGC-3’`

3.  Set2 forward: `5’-TGGATGGGTTCTCACTTCCTG-3’`

4.  Set2 reverse: `5’-GTCAATCCTTCGTATTGTGGCAT-3’`

5.  Set3 QuantiTect Primer Assays for Hs_SLC40A1 (QT00094843, Qiagen)

Results {#sec008}
=======

Routine practice of heating samples in Fpn1 (SLC40A1) western blot {#sec009}
------------------------------------------------------------------

According to the citation history for Fpn1 antibody in CiteAb, the rabbit polyclonal anti-Fpn1 antibody NBP1-21502 (Novus Biologicals) has been most successfully used in research article publications (<https://www.citeab.com/>). After preliminary testing of optimum dilutions of this primary antibody with either 5% skim milk or 1% BSA in Tween/TBS buffer, we decided to use 1,000--1,500-fold dilution in 1% BSA in Tween/TBS. We prepared WCL samples from several culture cell lines, heated at 95°C for 5min, loaded on a 10% acrylamide SDS-PAGE gel, and performed western blotting. The blot gave rise to multiple bands including the putative Fpn1 band\* (63 kDa) between 50 and 75 kDa size markers ([Fig 1A](#pone.0235563.g001){ref-type="fig"}).

![Heated samples for Fpn1 (SLC40A1) western blotting.\
**A)** 25ug of whole cell lysates (WCLs) prepared from indicated cells (\*two different preparations of SW480 WCLs) were subjected to Fpn1 western blotting as detailed in the Materials and Methods. This experiment used sample loading buffer containing 5% β-mercaptoethanol, heated at 95°C for 5 min, anti-Fpn1 antibody (Novus, rabbit polyclonal, 1,000-fold diluted with 1% BSA in T/TBS) at 4°C overnight followed by anti-rabbit IgG-HRP conjugated (8,000-fold diluted with 1% BSA in T/TBS) at room temperature for 1.5hr. Unless otherwise noted, the rest of western blots in this study were performed in the same procedures with or without sample heating prior to gel loading. **B)** SW480 cells were treated with 0.1--0.5mM FAC (ferric ammonium citrate), 2-100ug/ml cisplatin, or FAC 0.25mM plus cisplatin 10ug/ml for 18hr. 20ug of WCLs were subjected to Western blotting with anti-Fpn1 antibody (top). The membrane was soaked in the stripping solution at room temperature for 1hr, washed with T/TBS, and incubated with anti-ferritin H mouse monoclonal antibody (sc-135667, Santa Cruz Biotechnology). In A) and B), the asterisks indicate the predicted position (63 kDa) of the endogenous Fpn1. The experiments were repeated three times and the representative western blots are shown.](pone.0235563.g001){#pone.0235563.g001}

The expression of Fpn1 can be increased by high iron levels through dissociation of IRE-binding protein 1 and 2 (IRP1 and IRP2) from the iron-responsive element (IRE) in 5'-UTR of Fpn1 mRNA \[[@pone.0235563.ref022]\]. Additionally, another Fpn1 mRNA (termed FPN1B) transcribed from an alternative promoter lacks the IRE but has the same open reading frame, therefore FPN1B expression is not responsive to cellular iron status \[[@pone.0235563.ref038]\]. To characterize the putative Fpn1 band further, we treated SW480 cells with ferric ammonium citrate (FAC) or cisplatin that directly inhibits IRP2 binding to IRE \[[@pone.0235563.ref039]\] and performed western blotting. The putative 63 kDa faint band was not increased by FAC but slightly increased by cisplatin treatment in SW480 cells ([Fig 1B](#pone.0235563.g001){ref-type="fig"}). In contrast, ferritin H was significantly increased by FAC and cisplatin because ferritin H mRNA also contains a functional 5'-IRE \[[@pone.0235563.ref040], [@pone.0235563.ref041]\], suggesting that FAC and cisplatin treatments are working to drive 5'-IRE-dependent translational upregulation. Collectively, we demonstrate that the most popular anti-Fpn1 antibody gave rise to the band around 63 kDa but it did not show clear regulation through the IRP-IRE system in SW480 cells. Thus, without taking a positive control for western blotting, the identity of the 63 kDa band in [Fig 1](#pone.0235563.g001){ref-type="fig"} remained undetermined.

No solubilization problem but heating samples may compromise Fpn1 western blot {#sec010}
------------------------------------------------------------------------------

To validate the putative Fpn1 band and anti-Fpn1 antibody further, we made WCL from HEK293 cells transiently transfected with a human Fpn1 expression plasmid and performed western blotting in a routine sample preparation and heating protocol (see [Materials and Methods](#sec002){ref-type="sec"}). The overexpressed Fpn1 (untagged) gave rise to one specific band that was stuck on the top of the separation gel ([Fig 2A](#pone.0235563.g002){ref-type="fig"}).

![Comparison in Fpn1 (SLC40A1) western blotting between heated and unheated protein samples from Fpn1 transfected cells.\
**A)** WCL in RIPA buffer was prepared from HEK293 cells transfected with pCMV or pCVMFpn1. 25ug of the WCL mixed with 2X SDSPAGE sample loading buffer was heated at 95°C for 5min and subjected to Fpn1 western blotting. The arrow indicates the Fpn1 protein stuck on the top of the separation gel (also in B and C). **B)** WCL in RIPA buffer, in RIPA plus sonication for 10 seconds three times in ice-water, or in transmembrane protein extraction reagent (Five Photon Biochemicals) was prepared from HEK293 cells transfected with pCMV or pCVMFpn1(6ug, \*Fpn1: 12ug DNA). 15ug of the WCLs mixed with 2X SDSPAGE sample loading buffer were heated at 95°C for 5min or not heated (at room temperature), and subjected to Fpn1 western blotting. The arrowhead indicates the transfected Fpn1 band. **C)** WCLs in RIPA buffer from HEK293 cells transfected with pCMV or pCVMFpn1 were mixed with 2X SDSPAGE sample loading buffer containing 5% β-mercaptoethanol (regular), 4M urea, or both 5% β-mercaptoethanol and 4M urea. One sample set was heated at 95°C 5min, another set was not heated (at room temperature), and subjected to Fpn1 western blotting. Positions of molecular weight protein size marker are indicated on the left. The experiments were repeated three times and the representative western blots are shown.](pone.0235563.g002){#pone.0235563.g002}

This result indicates that the Fpn1 antibody (NBP1-21502, Novus Biologicals) can detect at least overexpressed human Fpn1 protein by western blotting, in which the Fpn1 protein appeared to be insolubilized or aggregated. To solve the potential solubilization problem first, we used three different cell lysis conditions; RIPA lysis buffer, RIPA plus sonication, and transmembrane extraction reagent (Five Photon Biochemicals). To solve the aggregation problem, we compared heated samples at 95°C to no heating (room temperature) of WCL from HEK293 transfected with pCMV-empty or -Fpn1 plasmid. As shown in [Fig 2B](#pone.0235563.g002){ref-type="fig"}, regardless of three different lysis conditions, transfected Fpn1 was stuck on the top of the gel when they were heated at 95°C prior to gel loading. In contrast, no heating samples gave rise to a specific Fpn1 band between 50 and 75kDa markers regardless of their different lysis conditions ([Fig 2B](#pone.0235563.g002){ref-type="fig"}). Furthermore, HEK293 WCL in RIPA mixed with three different 2X SDSPAGE sample loading buffers containing 5% β-mercaptoethanol (the regular sample loading buffer, see [Materials and Methods](#sec002){ref-type="sec"}), 4M urea, or both 5% β-mercaptoethanol and 4M urea did not improve the migration problem of overexpressed Fpn1 protein when they were heated ([Fig 2C](#pone.0235563.g002){ref-type="fig"}). By contrast, no heating of these WCL samples showed the right size of Fpn1 band regardless of the use of different loading buffers ([Fig 2C](#pone.0235563.g002){ref-type="fig"}). Taken together, we concluded that no heating of protein samples is the most critical factor for the right resolution and detection of transfected Fpn1 protein by western blotting with this anti-Fpn1 polyclonal antibody.

Heating samples compromised DMT1 (SLC11A2) western blot {#sec011}
-------------------------------------------------------

Another key SLC protein handling cellular iron traffic is DMT1 (SLC11A2). According to the citation data in CiteAb, there are more than 10 different anti-DMT1 antibodies used for publications. Among them, we used a rabbit monoclonal anti-DMT1 antibody (D3V8G, Cell Signaling Technology). To test whether heating protein samples also affects the resolution of DMT1 western blots, we prepared WCLs in RIPA or cytoplasmic and nuclear fractions from HEK293 cells transiently transfected with human DMT1 (untagged) or Flag-DMT1. Samples were mixed with 2x SDSPAGE sample loading buffer (containing 5% β-mercaptoethanol), heated at 95°C for 5min or left at room temperature, and performed SDS-PAGE and western blotting with anti-DMT1 or Flag antibody. As observed in the Fpn1 western blots in [Fig 2](#pone.0235563.g002){ref-type="fig"}, heating protein samples significantly impaired the DMT1 protein bands ([Fig 3A](#pone.0235563.g003){ref-type="fig"}). In clear contrast, no heating of samples (left at room temperature until sample loading) showed good resolution of \~75kDa and additional larger and smaller bands detected with anti-Flag ([Fig 3A](#pone.0235563.g003){ref-type="fig"}, top) as well as anti-DMT1 antibodies ([Fig 3A](#pone.0235563.g003){ref-type="fig"}, bottom). DMT1 mRNA isoforms contain 3'-UTR IRE \[[@pone.0235563.ref042]\] that should be subject to mRNA destabilization when IRP1 and/or IRP2 dissociates from the IRE in iron overloaded conditions or by inactivation of IRP2 following cisplatin treatment \[[@pone.0235563.ref039]\]. Indeed, endogenous DMT1 proteins were detected by western blotting in unheated WCLs isolated from SW480 cells treated with FAC (0.1--0.5 mM) or cisplatin (2--100 ug/ml), in which FAC or cisplatin treatment slightly decreased DMT1 protein levels ([Fig 3B](#pone.0235563.g003){ref-type="fig"}). Collectively, no heating of protein samples prior to loading to SDS-PAGE gel is critical for detection of transfected and endogenous DMT1 proteins by western blotting.

![Comparison in DMT1 (SLC11A2) western blotting between heated and unheated protein samples.\
**A)** WCL in RIPA buffer, or cytoplasmic (Cyto) and nuclear (Nuc) fractions were prepared from HEK293 cells transfected with pCMVFlag, pCMVDMT1 or pCVMFlagDMT1. 30ug of the WCL, Cyto, and Nuc fractions mixed with 2X SDSPAGE sample loading buffer were heated at 95°C for 5min or not heated (at room temperature), and subjected to western blotting with anti-Flag antibody (top) or anti-DMT1 antibody (bottom). **B)** WCLs in RIPA buffer were prepared from SW480 cells treated with 0.1--0.5mM FAC (ferric ammonium citrate), 2-100ug/ml cisplatin, or FAC 0.25mM plus cisplatin 10ug/ml for 18hr. 20ug of WCLs mixed with 2X SDSPAGE sample loading buffer without heating were subjected to Western blotting with anti-DMT1 antibody (top: longer exposure, bottom: shorter exposure). As a control, heated or unheated WCL from pCMVDMT1-transfected HEK293 cells was loaded. The experiments were repeated four times and the representative western blots are shown.](pone.0235563.g003){#pone.0235563.g003}

Effects of heating samples from 12 human cell lines on DMT1 and Fpn1 western blots {#sec012}
----------------------------------------------------------------------------------

To assess the effect of heating samples on detection of endogenous DMT1 and Fpn1 proteins in various cell types by western blotting, we prepared WCLs from 12 human cell lines (lysed in RIPA), mixed with 2x SDSPAGE sample loading buffer, heated at 95°C for 5min or not heated (left at room temperature), and performed SDSPAGE and Western blotting. Given the results of transfected Fpn1 and DMT1 in Figs [2](#pone.0235563.g002){ref-type="fig"} and [3](#pone.0235563.g003){ref-type="fig"}, only unheated WCLs from HEK293 cells transfected with empty vector, DMT1, and Fpn1 were loaded together as positive controls of western blots. As shown in [Fig 4A](#pone.0235563.g004){ref-type="fig"}, endogenous DMT1 proteins were detected in most of these human cell lines; however, heating samples at 95°C for 5min reproducibly impaired the major DMT1 band, some of which were stuck on the top of the gel (arrow on the right). Fpn1 western blots were more complicated because of multiple major bands in addition to no clear difference between heated and unheated samples ([Fig 4B](#pone.0235563.g004){ref-type="fig"}). This was an unexpected result because transiently transfected Fpn1 protein in HEK293 cells was detected only when the samples were not heated prior to loading to SDSPAGE gel ([Fig 2](#pone.0235563.g002){ref-type="fig"}). The Fpn1 western blotting was working in [Fig 4B](#pone.0235563.g004){ref-type="fig"} because transiently transfected Fpn1 used as a positive control was detected in the range between 50 and 75kDa size markers ([Fig 4B](#pone.0235563.g004){ref-type="fig"}). The endogenous protein showing the same migration as transfected Fpn1 was also detected in several cell types such as Caco-2 cells ([Fig 4B](#pone.0235563.g004){ref-type="fig"}).

![Comparison in DMT1 and Fpn1 western blotting between heated and unheated protein samples from 12 human cell lines.\
25ug of WCLs in RIPA buffer from indicated 12 human cell lines were mixed with 2X SDSPAGE sample loading buffer, either heated at 95°C for 5min or not heated (at room temperature), and subjected to **A)** DMT1 and **B)** Fpn1 western blotting. As a control, 10ug of non-heated WCL from HEK293 cells transfected with pCMV, pCMVDMT1, or pCMVFpn1 was loaded. The arrowheads indicate the positions of transfected DMT1 and Fpn1 bands. In A), the arrow indicates the DMT1 protein stuck on the top of the separation gel. The experiments were repeated four times and the representative western blots are shown.](pone.0235563.g004){#pone.0235563.g004}

As our Fpn1 western blots gave rise to multiple non-specific bands, we further verified the endogenous band migrating together with transfected Fpn1. First, transfection of Fpn1 siRNA into undifferentiated Caco-2 cells reduced Fpn1 mRNA level to 35.3% (p = 0.007 in unpaired t-test, FAC 0) and consistently diminished the endogenous protein band co-migrating with transfected Fpn1 ([Fig 5A](#pone.0235563.g005){ref-type="fig"}). Second, as hepcidin binds Fpn1 and induces Fpn1 internalization and degradation \[[@pone.0235563.ref043]\] in Caco-2 cells \[[@pone.0235563.ref044]\], we treated Caco-2 cells (3 plates each) with bioactive hepcidin at 500 ng/ml for 24hr and performed Fpn1 western blotting, in which hepcidin-treated cells appeared to have decreased Fpn1 protein levels ([Fig 5B](#pone.0235563.g005){ref-type="fig"}). Collectively, we concluded that the band co-migrating with transfected Fpn1 is the endogenous Fpn1 protein.

![Verification of the band specific to endogenous Fpn1 protein.\
**A)** Caco-2 cells were transfected with Control- or Fpn1-siRNA using Lipofectamine RNAiMax for 18hr, followed by treatment with FAC at the final 250 and 500uM for additional 8hr in the presence of siRNA. Unheated Caco-2 WCLs in RIPA buffer along with unheated WCL from HEK293 cells transfected with pCMV or pCVMFpn1 were analyzed by western blotting for Fpn1 (top) followed by incubation with anti-GAPDH antibody. **B)** Caco-2 cells were untreated or treated with 500nM hepcidin (3 plates each) for 22h. 20ug of three-independent hepcidin (-) and hepcidin (+) WCLs in RIPA buffer were mixed with 2X SDSPAGE sample loading buffer, unheated, and subjected to Western blotting with the anti-Fpn1 antibody. Unheated WCL from HEK293 cells transfected with pCMV or pCVMFpn1 was loaded as a control. The membrane was incubated with the anti-GAPDH antibody to assess an equal amount of sample loading. The experiments were repeated five times and the representative western blots are shown.](pone.0235563.g005){#pone.0235563.g005}

Effects of heating samples for single-transmembrane TfR1 and cytoplasmic ferritin western blots {#sec013}
-----------------------------------------------------------------------------------------------

We elucidated the effect of sample heating on western blots for two other key iron transport and storage proteins; single-transmembrane TfR1 and cytoplasmic ferritin. We prepared WCL in RIPA from Caco-2 cells treated with hemin, FAC, and an iron chelator deferoxamine (DFO) for 24hr. We compared heated samples with unheated samples for detection of each endogenous protein by western blotting. In Fpn1 western blotting, transiently transfected Fpn1 in HEK293 was reproducibly detected in unheated samples, whereas heated samples failed to show the right size of Fpn1 band between 50-75kDa protein size markers, rather showing very faint bands stuck on the top of the gel (arrow, [Fig 6A](#pone.0235563.g006){ref-type="fig"} right). FAC or hemin treatment in Caco-2 cells increased a band migrating similar to transfected Fpn1, in which the unheated group of samples showed slightly stronger bands compared to heated samples at 95°C for 5min ([Fig 6A](#pone.0235563.g006){ref-type="fig"}).

![Comparison in western blotting for ferritin and TfR1 proteins between heated and unheated samples from Caco-2 cells treated with iron.\
Caco-2 cells were untreated or treated with 50uM hemin, 250 and 500uM FAC, or 25uM DFO for 24hr. 25ug of Caco-2 WCLs along with 10ug of WCL from HEK293 cells transfected with pCMV or pCVMFpn1 were heated at 95°C for 5min or not heated (at room temperature). They were subjected to successive western blotting with **A)** anti-Fpn1 (SLC40A1), **B)** anti-DMT1 (SLC11A2), **C)** anti-ferritin H, **D)** anti-TfR1, and **E)** anti-GAPDH antibodies. The larger area of Fpn1 western blot for HEK293 cells transfected with pCMV or pCVMFpn1 is shown right next to the panel A. The arrow indicates the transfected Fpn1 protein stuck on the top of the separation gel. The asterisk in D) may be a TfR1 dimer only seen in unheated samples. The experiments were repeated three times and the representative western blots are shown. The same experiment repeated in HepG2 cells are shown in [S2 Fig](#pone.0235563.s002){ref-type="supplementary-material"}.](pone.0235563.g006){#pone.0235563.g006}

Conversely, we anticipated that the iron chelator DFO would inhibit translation of Fpn1 mRNA via the 5'-UTR IRE; however, we repeatedly failed to observe it ([Fig 5A](#pone.0235563.g005){ref-type="fig"}, DFO compared to none). The endogenous DMT1 was consistently detected only when samples were not heated ([Fig 6B](#pone.0235563.g006){ref-type="fig"}). In contrast, the H subunit of ferritin (ferritin H) was detected as increased by hemin or FAC treatment only in heated samples ([Fig 6C](#pone.0235563.g006){ref-type="fig"}). As ferritin is composed of 24 subunits of ferritin H and L, heat denaturation of samples is necessary for ferritin western blot otherwise we often observed no ferritin bands or ferritin stuck on the top of the gel ([S1 Fig](#pone.0235563.s001){ref-type="supplementary-material"}). Interestingly, western blot for an 85 KDa homodimer of a plasma single-transmembrane protein TfR1 showed that unheated samples gave much stronger bands in an iron-responsive manner (iron-mediated downregulation) than samples heated at 95°C for 5min ([Fig 6D](#pone.0235563.g006){ref-type="fig"}). The unheated samples gave rise to an additional higher molecular weight band, probably a dimer of TfR1, in an iron-responsive manner (asterisk in [Fig 6D](#pone.0235563.g006){ref-type="fig"}). The cytoplasmic protein GAPDH as a protein loading control was detected equally in both heated and unheated samples ([Fig 6E](#pone.0235563.g006){ref-type="fig"}). Similar results were observed in HepG2 WCLs except for the endogenous Fpn1 band showing no clear differences between heated and unheated samples, both of which showed clear iron-induced Fpn1 expression following FAC treatment ([S2 Fig](#pone.0235563.s002){ref-type="supplementary-material"}).

Discussion {#sec014}
==========

Western blotting techniques were improved and seemingly have established, which may make us often omit in publications describing critical steps and tips for detection of protein of interest in western blotting. This is partly because a standard protocol for sample preparation has a routine protein denaturation step by heating at 95--100°C in a sample loading buffer containing SDS and a reducing agent such as β-mercaptoethanol or dithiothreitol. This heating step is understood important for antibodies to find epitopes efficiently as well as to detect a specific protein in multiple protein binding complexes or a subunit of multimeric proteins as exemplified by the detection of ferritin in this study ([Fig 6C](#pone.0235563.g006){ref-type="fig"}). However, detection of transmembrane proteins by western blotting seems to be more challenging and complicated. There are more than 3,000 human genes encoding transmembrane proteins, in which \~ 1,300 receptors including seven-transmembrane GPCR (G protein coupled receptor) and single-pass transmembrane receptors, \~ 800 transporters such as SLC, ABC (ATP binding cassette) transporters, and channels, and \~ 500 enzymes including transferases, hydrolases, and oxidoreductases \[[@pone.0235563.ref001]\]. We sometimes find researcher's troubleshooting discussions via internet medias about unsuccessful western blotting for detection of particular transmembrane proteins. Along with our initial failure to detect SLC family iron transporters in this study, we anticipate that routine heat denaturing protocols may not work or significantly loose band signals in western blotting to detect many more transmembrane and heat-sensitive proteins, perhaps due to heat-induced protein aggregations and/or conformational changes.

In this study, we observed that non-heated samples solely solved the migration and resolution problems of DMT1 and overexpressed Fpn1 western blots, whereas three different cell lysis conditions or three different 2X sample loading buffers did not improve the situation ([Fig 2](#pone.0235563.g002){ref-type="fig"}). Despite the fact that both DMT1 and Fpn1 are 12-transmembrane proteins \[[@pone.0235563.ref013], [@pone.0235563.ref015], [@pone.0235563.ref028], [@pone.0235563.ref029]\], heating samples at 95°C for 5min ruined DMT1 western blot (Figs [3](#pone.0235563.g003){ref-type="fig"}, [4A](#pone.0235563.g004){ref-type="fig"} and [6B](#pone.0235563.g006){ref-type="fig"}) whereas only partially impaired endogenous Fpn1 western blot (Figs [4B](#pone.0235563.g004){ref-type="fig"} and [6A](#pone.0235563.g006){ref-type="fig"}). However, heating samples completely impaired the migration of transfected Fpn1 (untagged) being stuck on the top of the separation gel ([Fig 2A](#pone.0235563.g002){ref-type="fig"}). We do not have good explanations for these different outcomes in sample heating between DMT1 and Fpn1 12-TMS proteins and between transfected and endogenous Fpn1 proteins. However, these results alert us to be aware of potentially different effects of sample heating on western blotting of any other SLC transporters and transmembrane proteins. It is therefore important to find the optimum condition of sample preparation for each transmembrane protein western blotting. This was also the case in TfR1 western blotting, in which non-heated samples tended to give rise to stronger and consistent iron status-dependent TfR1 band despite showing the additional TfR1 dimer band ([Fig 6D](#pone.0235563.g006){ref-type="fig"}, [S2 Fig](#pone.0235563.s002){ref-type="supplementary-material"}). In contrast, heating samples was essential for detection of cytoplasmic ferritin H subunit protein in western blotting because ferritin is assembled of 24 subunits of H and L proteins \[[@pone.0235563.ref011]\]. These results suggest that a single western blot loaded only either heated or non-heated protein samples cannot be used for successive reprobing with DMT1, Fpn1, TfR1, and ferritin antibodies. Another cytoplasmic protein GAPDH, often used as a protein loading control of western blotting, was not affected by heated or unheated protein samples. It should be noted that, although we observed no improvement for Fpn1 western blotting by switching from RIPA to RIPA plus sonication or commercially available membrane protein extraction lysis buffer ([Fig 2A](#pone.0235563.g002){ref-type="fig"}), the lysis buffer components together with mechanical destruction of membranes may also significantly improve western blotting for some other transmembrane proteins more than the impact of heating protein samples.

It may be a routine practice for laboratories and researchers primarily working on transmembrane proteins to avoid heat-denaturing protein samples prior to gel loading. Alternatively, they may have additional technical tips for particular transmembrane protein western blotting that we have not tested in this study. Indeed, no sample heating prior to gel loading for Fpn1 western blotting was noted in some earlier publications \[[@pone.0235563.ref022], [@pone.0235563.ref026], [@pone.0235563.ref028]\], while we observed relatively few attempts of DMT1 western blotting in earlier publications or no particular notes for western sample preparations except examples such as pre-incubation at 37°C for 15min by Nam et al \[[@pone.0235563.ref045]\]. CiteAb records more than 50 citations for several applications with the rabbit polyclonal anti-Fpn1 antibody (NBP1-21502, Novus Biologicals) that we used in this study, in which more than 30 publications used this antibody for western blotting. Most of them did not clarify sample heating conditions or heated at 90--100°C, except 75°C for 10min \[[@pone.0235563.ref046]\] or no heating \[[@pone.0235563.ref039]\]. Even if protein samples might have been preheated in most of these publications, they might have observed the right size of the endogenous Fpn1 band as we observed in this study (Figs [4B](#pone.0235563.g004){ref-type="fig"} and [6A](#pone.0235563.g006){ref-type="fig"}). CiteAb also lists more than 10 publications for DMT1 western blotting using Proteintech, Abcam, or Novus Biologicals anti-DMT1 antibody, only some of which noted that they treated samples with gentle heating at 37°C for 30min \[[@pone.0235563.ref047]--[@pone.0235563.ref049]\] or 50°C for 15min \[[@pone.0235563.ref050]\]. Anti-DMT1 antibodies that have different epitopes from our anti-DMT1 antibody (Cell Signaling Technology, near the N-terminus of human DMT1) may also affect the optimum conditions of protein sample preparation for better resolution of western blotting.

Conclusion {#sec015}
==========

In summary, only non-heated protein samples worked for western blotting with the anti-DMT1 (SLC11A2) monoclonal antibody having the epitope near the N-terminus. Non-heated protein samples gave rise to better resolution and/or stronger band signals in western blotting with anti-Fpn1 (SLC40A1) and anti-TfR1 polyclonal antibodies. Three different lysis buffers, three sample loading buffers, or sample sonication we tested did not improve the resolution of DMT1 and Fpn1 western blots. In contrast, only heated protein samples worked for ferritin western blotting with the anti-ferritin H monoclonal antibody, while sample heating did not affect western blotting for another cytoplasmic protein GAPDH frequently used for a protein loading control. Collectively, either heated or unheated samples most critically determined the quality and outcome of transmembrane protein western blotting we tested, suggesting that there should be many similar cases for western blotting of other transmembrane and heat-sensitive proteins.

Supporting information {#sec016}
======================

###### Unheated samples compromise ferritin western blotting.

WCLs in RIPA buffer were prepared from SW480 cells treated with 0.1--0.5mM FAC (ferric ammonium citrate), 10 or 25ug/ml cisplatin for 18hr. 20ug of WCLs mixed with 2X SDSPAGE sample loading buffer without heating and 25uM cisplatin WCL without or with heating at 95°C, 5min were subjected to Western blotting with anti-ferritin H antibody, followed by incubation with anti-GAPDH antibody. The arrow indicates the ferritin protein stuck on the top of the separation gel.

(TIFF)

###### 

Click here for additional data file.

###### Comparison in western blotting for iron metabolism proteins between heated and unheated protein samples from HepG2 cells treated with iron.

HepG2 cells were untreated or treated with 100, 250uM FAC, or 25uM DFO for 24hr. Caco-2 cells were untreated or treated with 250uM FAC for 24hr. 30ug of HepG2, Caco-2 WCLs along with 10ug of WCL from HEK293 cells transfected with pCMV or pCVM Fpn1 were heated at 95°C for 5min or not heated (at room temperature). They were subjected to successive western blotting with **A)** anti-Fpn1, **B)** anti-DMT1, **C)** anti-TfR1, **D)** anti-ferritin H, and **E)** anti-GAPDH antibodies. The arrow in A) indicates the transfected Fpn1 protein stuck on the top of the separation gel. The asterisk in C) may represent a TfR1 dimer.

(TIFF)

###### 

Click here for additional data file.

###### Original entire blots for figures.

(PDF)

###### 

Click here for additional data file.

10.1371/journal.pone.0235563.r001

Decision Letter 0

Missirlis

Fanis

Academic Editor

© 2020 Fanis Missirlis

2020

Fanis Missirlis

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

13 May 2020

PONE-D-20-06977

Transmembrane Protein Western Blotting: Impact of Sample Preparation on Detection of SLC11A2 (DMT1) and SLC40A1 (ferroportin)

PLOS ONE

Dear Dr. Tsuji,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please address all comments by reviewers, who are in general supportive of the publication of these results. There are two issues of concern, one related to repetitions/statistics, where I ask the authors for clarity above all. Likewise, there was some concern of the use of photoshop in some of the figures, please read carefully and adhere to PLOS One policy with respect to the images and state that you have done so in your reply.

We would appreciate receiving your revised manuscript by Jun 07 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Fanis Missirlis, Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and

<https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. Thank you for stating the following in the Acknowledgments Section of your manuscript:

\"Funding:

This work was supported in part by P30ES025128 from the National Institute of

Environmental Health Sciences to the Center for Human Health and the Environment

(CHHE).\"

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please provide an amended statement that declares \*all\* the funding or sources of support (whether external or internal to your organization) received during this study, as detailed online in our guide for authors at [[http://journals.plos.org/plosone/s/submit-now](about:blank)]{.ul}.  Please also include the statement "There was no additional external funding received for this study." in your updated Funding Statement.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

\"The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.\"

3\. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission's figures or Supporting Information files. This policy and the journal's other requirements for blot/gel reporting and figure preparation are described in detail at <https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements> and <https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files>. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: <https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels>.

In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at <plosone@plos.org> if you have any questions.

4\. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see <http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions>.

In your revised cover letter, please address the following prompts:

a\) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b\) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of acceptable repositories, please see <http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories>.

We will update your Data Availability statement on your behalf to reflect the information you provide.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: No

Reviewer \#2: N/A

Reviewer \#3: No

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: PLOS ONE

Transmembrane Protein Western Blotting: Impact of Sample Preparation

Overview: A study investigating the effect of heating vs non-heating of protein samples prior to loading and its subsequent effect on detection of SLC11A2, SLC40A1 and TfR1.
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This work is based on initial observation of the Author concerning a mediocre functioning of SLC11A2 and SLC40A1 antibodies in his routine western blotting protocol. In the MS Author nicely and adequately explains, step by step, how specific modifications in sample preparation lead to significant improved western blot resolution for membrane proteins.
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Remarks

The authors relate in the abstract to DMT1 as an iron exporter. In most cases it though functions as an importer, when viewing the cytosol of a cell as "in" and the endosome as a part of internalized "out". Later in the text DMT1 is termed a "transporter", which does it more justice.
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In the text, a reference to fig. 2A is missing.
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Response to Reviewers

Manuscript ID\#: PONE-D-20-06977

Manuscript Title: Transmembrane Protein Western Blotting: Impact of Sample Preparation on Detection of SLC11A2 (DMT1) and SLC40A1 (ferroportin)

Corresponding Author: Dr. Yoshiaki Tsuji

Reviewer \#1

Overview: A study investigating the effect of heating vs non-heating of protein samples prior to loading and its subsequent effect on detection of SLC11A2, SLC40A1 and TfR1. Research groups have previously published SLC11A2 and SLC40A1 Western blots where the protein samples were heated prior to loading. Heating samples did not affect the bands in these studies 1,2. The author describes in the discussion, research groups have also previously published western blots where the samples were not heated prior to loading. Therefore, I am uncertain about the novelty of this study. Unfortunately, this was a very confusing paper to follow. The use of 12 cell lines to investigate the effect of heating may have been the reason for this confusion. My advice is to select a few cell lines which are involved in iron metabolism (i.e: Caco-2 and HepG2) and investigate what effect heating vs non-heating has on iron proteins from lysates obtained from these lines. Moreover, it would be useful to see if the effects observed are also present when other commercially available antibodies are used.

Response: Thank you for very constructive and helpful overview.

First, we have never published SLC11A2 (DMT1) western blotting, retrospectively it was not successful because we routinely heated our samples and failed to detect convincing DMT1 bands.

Second, yes this reviewer is right; we published SLC40A1 (Fpn) western blots using unheated samples in very low Fpn1-expressing cells (Cell Chem. Biol., 26:85-97, 2019).

Third, as this reviewer pointed out, several papers showing DMT1 or Fpn1 western blots (in addition to the reviewer's ref. 1 and 2) used heated samples (e.g. 100oC 10 min, 90oC 2 min, 75oC 10 min, 37oC 30 min), while most papers did not describe specific conditions for preparation of protein samples (discussed in this manuscript). I feel that some of published western blots for DMT1 (probably Fpn1 also) as well as some other SLC family members may not be accurate (particularly blots without indicating positions of protein size markers) or detected only partial quantities that did not aggregate even after heating, as seen in Figures 4 and 6. Please note that we have the following statement in the discussion (page 24) for PLOS ONE readers: "Indeed, no sample heating prior to gel loading for Fpn1 western blotting was noted in some earlier publications (22, 26, 28), while we observed relatively few attempts of DMT1 western blotting in earlier publications or no particular notes for western sample preparations except examples such as pre-incubation at 37oC for 15 min by Nam et al (44)".

Forth, all cell lines used in this study, including Caco-2 and HepG2, tightly regulate iron metabolism in response to environmental cues therefore have been used for investigation of the mechanisms of iron transport and storage. We hope that showing our results in all these cell lysates would help more researchers perform DMT1, Fpn1, or other transmembrane protein western blots with specific antibodies used in this study as well as their specific antibodies.

We appreciate all of these reviewer's important points.

Comment 1.1 Methods: Please include a section about cell culture maintenance.

Response: A new section of "Cell Culture and Maintenance" has been created in the Materials and Methods (page 6).

Comment 1.2 Please indicate how many days following transfection were the Caco-2 cells used?

Response: We have included the experimental timeline in the sub-section of Plasmids, siRNA, and Transfection in the Materials and Methods, page 12).

Comment 1.3 Did the authors verify knockdown using qPCR?

Response: Yes, we verified Fpn1 knockdown in untreated Caco-2 cells in the experiment shown Fig. 5A. The qPCR results (35.3%, p=0.007: Fpn1 mRNA with transfection of siFpn1 compared to siControl) were included in the main text (page 18) without showing the graph in order to stay focus on technical tips in transmembrane western blotting. The qPCR methods and primer sets have been included accordingly in the Materials and methods (page 11).

Comment 1.4 Were Caco-2 cells undifferentiated/differentiated when lysed?

Response: They were undifferentiated. In the revised manuscript, we have added a note that "undifferentiated Caco-2 cells were used in this study" in the "Cell Culture and Maintenance" section (page 6) along with in the main text (page 18). Thank you.

Comment 1.5 Results: Please include figure captions.

Response: Thank you, we have included figure captions in all figures.

1\. Kondaiah P, Aslam MF, Mashurabad PC, Sharp PA, Pullakhandam R. Zinc induces iron uptake and DMT1 expression in Caco-2 cells via a PI3K/IRP2 dependent mechanism. Biochemical Journal. 2019;476(11):1573-1583.

2\. Scheers NM, Almgren AB, Sandberg A-S. Proposing a Caco-2/HepG2 cell model for in vitro iron absorption studies. The Journal of nutritional biochemistry. 2014;25(7):710-715.

Reviewer \#2

In the present work, Author Yoshiaki Tsuji investigated the impact of sample preparation for an optimal detection by western blotting of specific transmembrane proteins, SLC11A2 (DMT1) and SLC40A1 (ferroportin). This work is based on initial observation of the Author concerning a mediocre functioning of SLC11A2 and SLC40A1 antibodies in his routine western blotting protocol. In the MS Author nicely and adequately explains, step by step, how specific modifications in sample preparation lead to significant improved western blot resolution for membrane proteins. As far as technical issue for an optimal study of transmembrane protein is concerned, the MS deals about a subject of great interest and concerns proteins involved in iron metabolism, for which Author's expertise is well established. That said I have two minor points to address to the Author:

Comment 2.1: Discussion, first page. The sentence beginning with "Given researcher's troubleshooting discussions..." should be rephrased because it is too long and complex in this present form.

Response: Thank you, I totally agree. In the revised manuscript, it has been divided into two sentences and corrected to "We sometimes encounter researcher's troubleshooting discussions via internet medias about unsuccessful western blotting for detection of particular transmembrane proteins. Along with our initial failure to detect SLC family iron transporters in this study, we anticipate that....." (page 22)

Comment 2.2: I understand protocols were tested on different cell lines. Were lysates from primary cell cultures been also tested?

Response: I have not tested primary culture cells. I understand this reviewer's point that inclusion of primary culture cells would be helpful to more researchers having the transmembrane western problem. I expect that this study will be basically applicable to primary cultures. Readers will first test heating and lysis buffer conditions in their primary culture samples as demonstrated in this study, which hopefully could provide them with solutions or a better idea of further trouble shooting.

Reviewer \#3

The manuscript addresses the question how different sample preparation has major affects on the outcome of Western blotting of several proteins related to iron metabolism. This is a worthy study as it can save many researchers a lot of pain, and improve study-outcomes.

Comment 3.1: The authors relate in the abstract to DMT1 as an iron exporter. In most cases it though functions as an importer, when viewing the cytosol of a cell as "in" and the endosome as a part of internalized "out". Later in the text DMT1 is termed a "transporter", which does it more justice.

Response: We totally agree with the important point. The abstract has been revised as follows:

transmembrane iron transporter proteins; SLC11A2 (divalent metal transporter 1, DMT1), SLC40A1 (ferroportin 1, Fpn1), and transferrin receptor-1 (TfR1),

Comment 3.2: It would be much clearer to use Fpn and DMT1 throughout the paper, and not label the figures in one way and use in the text the SLC terms, sometimes in full and sometimes shortened e.g. SLC40.

Response: This is another important issue we realized after reading the manuscript carefully. In the revised manuscript, we primarily use Fpn1 and DMT1 rather than SLC40A1 and SLC11A2, respectively. All changes have been yellow-highlighted. Thank you for very helpful suggestions.

Comment 3.3: In the text, a reference to fig. 2A is missing.

Response: We have confirmed a reference to Fig. 2A in the text (page 13).

Comment 3.4: In Figure 3 B, the evidence for a decrease of DMT1 with increased FAC is weak and the decrease with increased Cisplatin is not convincing at all. Can you please quantify these graphs and also indicate how often each experiment was repeated. Indicate the number of times the experiments were repeated throughout the manuscript, best in the legends.

Response: We agree with the point of the small DMT1 expression changes in Fig. 3B (and also Fig. 6B). As 1) the trend of slightly decreased DMT1 expression in response to iron treatment is consistent in Fig. 3B and 6B, and 2) this manuscript primarily focuses on technical tips in transmembrane western blotting, we have just tempered the original statement in the text by adding "slightly" decreased DMT1 protein levels (Fig. 3B) at page 16. The experimental repeats have been indicated in each figure legend.

Comment 3.5: There seems to be a discrepancy between Fpn results in fig. 6a and 4b. Any explanation?

Response: Thank you for paying attention to this point. Although there might be a slight difference between these Fpn1 western blots in Caco-2 cells, the trend was similar; namely, heating samples did not compromise Fpn1 western blotting except for transfected (overexpressed) Fpn1.

Comment 3.6: Figure legend 1 has a different format than the other legends, giving lot's of info on blocking and washes. Could be omitted. Giving these details in materials and methods is enough.

Response: We agree with simplifying the figure legend 1. As suggested, we have dropped redundant information including blocking and washing procedures.
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Dear Dr. Tsuji,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.
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